Champions Oncology, INC 10-Q quarterly reports

Champions Oncology reported a net loss for the third quarter and nine months ended January 31, 2026, driven by a significant decline in TOS data license revenue and increased operating expenses.

Champions Oncology reported a net loss for the six months ended October 31, 2025, despite revenue growth, driven by increased investments in R&D and its data licensing platform.

Champions Oncology, Inc. reported a net loss of $0.44 million for the first fiscal quarter of 2026, a significant decline from a $1.31 million net income in the prior year, driven by increased R&D and operating costs.

Champions Oncology's Q3 2025 revenue increased by 41.8% year-over-year, driven by growth in pharmacology services and data license sales.

Champions Oncology reports a net income of $2.041 million for the six months ended October 31, 2024, a significant turnaround from a net loss of $4.637 million in the same period last year, driven by a 14.2% increase in oncology services revenue.

Champions Oncology reports a net income of $1.3 million for the quarter ended July 31, 2024, a significant turnaround from a net loss in the same period last year, with revenue increasing by 11.9%.

Champions Oncology's Q3 2024 results show a decrease in revenue and an increased net loss compared to the same period last year, primarily due to higher study cancellations.